Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol

Trial Profile

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Metoprolol (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms PRADA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Feb 2016 Primary endpoint of left ventricular ejection fraction has not been met, according to results published in the European Heart Journal.
    • 12 Feb 2016 Results published in the European Heart Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top